Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression

Tina Roya Division of Hematology and Oncology Georgetown University School of Medicine Washington, DC, USACorrespondence[email protected]

https://orcid.org/0000-0001-9065-7601

Joseph B. Ana Division of Hematology and Oncology Georgetown University School of Medicine Washington, DC, USA

Kimberly Doucettea Division of Hematology and Oncology Georgetown University School of Medicine Washington, DC, USA

Aimee M. Chappella Division of Hematology and Oncology Georgetown University School of Medicine Washington, DC, USA

David H. Vesolea Division of Hematology and Oncology Georgetown University School of Medicine Washington, DC, USA;b Myeloma Division, John Theurer Cancer Center at Hackensack Meridian School of Medicine Hackensack, NJ

https://orcid.org/0000-0001-7721-3870

References

Gonsalves WI, Buadi FK, Kumar SK. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). Eur J Haematol. 2018;100(2):215–217.
PubMed Web of Science ®Google Scholar
Dhakal B, Patel S, Girnius S, et al. Hematopoietic cell transplanation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020;34(12):3338–3347.
PubMed Web of Science ®Google Scholar
Kaufman JL, Gasparetto C, Schjesvold FH, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. Am J Hematol. 2021;96(4):418–427.
PubMed Web of Science ®Google Scholar
Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630–1642.
PubMed Web of Science ®Google Scholar
Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue - a review. Diagn Pathol. 2014;9:221.
PubMed Web of Science ®Google Scholar
Valliani S, Ali M, Mahmoo O, et al. Efficacy of venetoclax and dexamethasone in refractory IgM primary plasma cell leukemia with t(11;14) and TP53 mutation: a case report and literature review. Case Rep Hematol. 2020;2020:8823877.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date